therapeutic action: mood enhancement

Psilocybin for clinical indications: A scoping review

mycolabadmin

This comprehensive review examined over 190 research studies on psilocybin (the active compound in magic mushrooms) as a medical treatment. The research shows promise for treating depression, anxiety, substance use disorders, and chronic pain, though most studies conducted so far have been small in size. While the evidence is encouraging, researchers emphasize the need for larger, better-designed clinical trials to fully understand psilocybin’s benefits and safety profile.

Read More »

Cystathionine Gamma-Lyase Regulate Psilocybin Biosynthesis in Gymnopilus dilepis Mushroom via Amino Acid Metabolism Pathways

mycolabadmin

Researchers studying the ‘magic mushroom’ Gymnopilus dilepis discovered that a specific enzyme called CTH plays a crucial role in producing psilocybin, the compound with potential antidepressant effects. By blocking this enzyme, they reduced psilocybin production, but adding a related compound called L-cysteine restored it. This finding suggests that controlling amino acid metabolism could help increase psilocybin production for medical use.

Read More »

Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery

mycolabadmin

This study surveyed athletes and sports staff in Canada and the United States about their views on using psilocybin-assisted therapy to treat concussion symptoms. Researchers found that about 36% of athletes had used psychedelics in the past year, with psilocybin being the most common. Most athletes (61%) and staff (71%) said they would be willing to try or support psilocybin therapy for concussion recovery if research showed it was beneficial. The main factor influencing willingness was knowledge about psilocybin and positive attitudes toward it.

Read More »

A Review of the Food and Drug Administration Pipeline and Proposed California Legislation on Medicinal Psychedelics

mycolabadmin

Psychedelic compounds like psilocybin and ketamine show promise in treating serious mental health conditions including PTSD and depression. The FDA carefully evaluates these drugs through multi-phase clinical trials to ensure they are safe and effective. While California has proposed making psychedelics more widely available through legislation, the FDA’s thorough approval process provides important protections by identifying potential risks and ensuring proper medical oversight.

Read More »

Psychedelic-assisted psychotherapy: The need to monitor adverse events

mycolabadmin

While psychedelics show promise for treating depression and other mental health conditions, researchers need better systems to monitor and report any harmful effects they might cause. This paper calls for more careful, consistent tracking of both physical changes (like blood pressure) and psychological experiences during psychedelic therapy. The authors emphasize that safety monitoring should continue even after patients leave the clinic and that women may experience different side effects than men.

Read More »

“Plants of the Gods” and their hallucinogenic powers in neuropharmacology — A review of two books

mycolabadmin

This review examines two books about plants that have been used in religious and healing rituals across many cultures for their mind-altering properties. The author verifies that the hallucinogenic plants described in Carlos Castaneda’s popular books about a Yaqui sorcerer are accurately portrayed pharmacologically. The review explains how different sacred plants like peyote, certain mushrooms, and nightshade varieties affect the brain through various chemical pathways, while noting their dangers when misused.

Read More »
Scroll to Top